Vericel Corp (VCEL)
Biological Products, (No Diagnostic Substances)
Latest Price
$39.72
TTM P/E
82.75
Normalized P/E
19860.00
Div Yield
--
Book Value
7.27
P/B Ratio
5.47
Valuation metrics
adjust assumptions →EPS: $0.32
Book value / share: $7.01
Formula: √(22.5 × EPS × BVPS)
Graham Number
$7.10
82% downside
Base FCF: $18M (median of recent 5yr)
Growth: 25%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$29.49
26% downside
EPS: $0.32
Target P/E: 83×
Formula: EPS × P/E
P/E Fair Value
$26.56
33% downside
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.09M | $360.0M | 15.81% | +326.9K | 2026-06-30 |
| STATE STREET CORP | 3.29M | $146.0M | 6.44% | +141.8K | 2026-06-30 |
| CONGRESS ASSET MANAGEMENT CO | 2.92M | $129.0M | 5.70% | +1.41M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.26M | $100.0M | 4.41% | +25.0K | 2026-06-30 |
| Conestoga Capital Advisors, LLC | 2.08M | $92.0M | 4.07% | -379.5K | 2026-06-30 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.99M | $88.0M | 3.89% | +160.1K | 2026-06-30 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.64M | $72.0M | 3.20% | -83.6K | 2026-06-30 |
| GW&K Investment Management, LLC | 1.55M | $68.0M | 3.03% | -66.4K | 2026-06-30 |
| Soleus Capital Management, L.P. | 1.46M | $64.0M | 2.85% | -1.09M | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.34M | $59.0M | 2.62% | +86.4K | 2026-06-30 |